187269-40-5
187269-40-5 結構式
基本信息
Bimosiamose
[1,1'-Biphenyl]-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis[6'-(α-D-mannopyranosyloxy)-
物理化學性質(zhì)
0.1 M NaOH:25.0(Max Conc. mg/mL);28.97(Max Conc. mM)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-106139 | Bimosiamose Bimosiamose | 187269-40-5 | 1mg | 600元 |
| 2025/02/08 | HY-106139 | Bimosiamose Bimosiamose | 187269-40-5 | 5mg | 1800元 |
| 2025/02/08 | HY-106139 | Bimosiamose | 187269-40-5 | 10 mg | 3000元 |
常見問題列表
IC50: 88 μM (E-selectin), 20 μM (P-selectin), 86 μM (L-selectin)
Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils.
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved.
| Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R) |
| Dosage: | 25 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed a significant increase in survival compared with controls. |